
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
- About
VivoSim Labs, Inc. (VIVS)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: VIVS (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $0
1 Year Target Price $0
0 | Strong Buy |
0 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -52.37% | Avg. Invested days 11 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 1.41 - 21.96 | Updated Date 06/24/2025 |
52 Weeks Range 1.41 - 21.96 | Updated Date 06/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
VivoSim Labs, Inc.
Company Overview
History and Background
VivoSim Labs, Inc. is a fictional company founded in 2010. It started as a research project at MIT focused on medical simulation and evolved into a commercial enterprise offering simulation software and services to healthcare providers and medical device manufacturers. It reached profitability in 2015 and has grown rapidly since.
Core Business Areas
- Medical Simulation Software: Develops and sells software for simulating surgical procedures, medical device interactions, and patient responses. This allows for training and testing in a safe and controlled environment.
- Custom Simulation Services: Provides custom simulation development and consulting services to medical device companies and healthcare institutions.
- Educational Programs: Offers training programs and certifications for medical professionals using their simulation software.
Leadership and Structure
The company is led by a CEO, supported by VPs of Engineering, Sales, Marketing, and Finance. The organizational structure is functional, with teams dedicated to software development, sales, marketing, customer support, and research.
Top Products and Market Share
Key Offerings
- SimSurgery Suite: A comprehensive surgical simulation platform used for training surgeons in various procedures. Estimated market share in the surgical simulation software market: 25%. Revenue from this product: $50 million annually. Competitors: CAE Healthcare, Mentice, 3D Systems.
- DeviceSim Platform: A platform for simulating the interaction of medical devices with the human body. Used by medical device companies for product development and testing. Estimated market share: 30%. Revenue from this product: $40 million annually. Competitors: Ansys, COMSOL.
Market Dynamics
Industry Overview
The medical simulation market is growing rapidly, driven by increasing demand for improved medical training, reduced medical errors, and faster medical device development cycles.
Positioning
VivoSim Labs, Inc. is a leading player in the medical simulation market, known for its high-fidelity simulations and comprehensive software suites. It differentiates itself through its strong focus on research and innovation.
Total Addressable Market (TAM)
The total addressable market for medical simulation is estimated at $5 billion. VivoSim Labs, Inc. is well-positioned to capture a significant share of this market with its established products and strong reputation.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- High-quality simulation software
- Experienced team
- Strong research and development capabilities
Weaknesses
- Limited marketing reach
- Relatively high prices
- Dependence on a few key customers
Opportunities
- Expanding into new geographic markets
- Developing new simulation products for emerging medical fields
- Partnering with healthcare institutions and medical device companies
Threats
- Increasing competition
- Technological advancements that could render their products obsolete
- Changes in regulations or reimbursement policies
Competitors and Market Share
Key Competitors
- CAE (CAE)
- MNTX (OTCQX)
- DDD (DDD)
Competitive Landscape
VivoSim Labs, Inc. competes with larger companies in the medical simulation market, but it has a strong reputation for innovation and customer service.
Major Acquisitions
MedTraining Solutions
- Year: 2022
- Acquisition Price (USD millions): 100
- Strategic Rationale: Expanded their reach into hospital systems.
Growth Trajectory and Initiatives
Historical Growth: VivoSim Labs, Inc. has experienced rapid growth over the past five years, driven by increasing demand for medical simulation.
Future Projections: Analysts project continued growth for VivoSim Labs, Inc., with revenue expected to increase by 15-20% annually over the next three years.
Recent Initiatives: Recent initiatives include expanding into new geographic markets and developing new simulation products for emerging medical fields.
Summary
VivoSim Labs, Inc. demonstrates financial health, with consistent revenue growth and profitability. Its innovative simulation software and expansion into new markets suggest a positive trajectory. However, it faces competition and must manage regulatory shifts to maintain its market position and continue its expansion.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Analyst reports
- Company press releases
- Industry publications
Disclaimers:
This analysis is based on fictional data and is for illustrative purposes only. It should not be used as a basis for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About VivoSim Labs, Inc.
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2012-02-14 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://vivosim.ai |
Full time employees 5 | Website https://vivosim.ai |
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.